OcuMension’s NCX 470 (OT-301), to lower intraocular pressure in patients with open-angel glaucoma or ocular hypertensions, has its NDA accepted for review by the NMPA. OcuMension has commercialisation rights to the product – from Nicox – in China, Korea, and South East Asia.